© Copyright 2012 Chemical Biology Ventures Limited. All Rights Reserved. Registered in England & Wales number 7968150. Registered office: 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ. Address for correspondence: 123 Alexander Close, Abingdon, Oxfordshire, OX14 1XD

CBVlogo4

Preclinical studies

Preclinical evaluation

Link button

Contact CBV

Tel: +44 (0) 1235 532481

Mob:          07836 554231

Email: [email protected]

Progressing from in vitro to in vivo studies can be a critical time for a project. Going too early & generating poor results can kill a project. Delaying too long costs time & money. It is important to plan the right studies and to identify the right CRO.

 

CBV has experience in achieving this important project milestone across multiple therapeutic areas, with both biologicals & new chemical entities & can provide the guidance you may need.

Reference Link:

 

Lord BI, Woolford LB, Wood LM, Czaplewski LG, McCourt M, Hunter MG, Edwards RM.  Mobilisation of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha.  Blood 85(12) 3412-3415, 1995.

 

Hunter MG, Bawden L, Brotherton D, Craig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM, Lewis PJ.  BB-10010: An active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.  Blood 86 (12) 4400-4408, 1995.

 

Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown D, Baker PJ, Barynin VV, Rice DW, Sedelnikova SE, Heal JR, Sheridan JM, Aiwale ST, Chauhan PK, Srivastava A, Taneja A, Collins I, Errington J, Czaplewski LG. A novel inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321, 1673-1675.

 

Haydon DJ, , Bennett JM, Brown D, Collins I, Lancett P, Stokes NR, Macdonald R, Chauhan PK, Sutariya JK, Nayal N, Srivastava A, Beanland J, Hall R, Henstock V, Noula C, Rockley C, Czaplewski LG. (2010). Building an antibacterial with in vivo efficacy: synthesis and characterisation of potent inhibitors of the bacterial cell-division protein FtsZ with improved pharmaceutical properties. J. Med Chem. 53, 3927-3936.